Vanguard Group Inc. Buys 702,418 Shares of Dyne Therapeutics, Inc. $DYN

Key Points

• Vanguard Group Inc. increased its stake in Dyne Therapeutics by 10.5%, owning approximately 6.52% of the company, valued at $77.47 million as of the latest SEC filing.
• Multiple institutional investors are showing interest, with GAMMA Investing LLC increasing its holdings by 837.5% during the first quarter, and overall, institutional investors own 96.68% of Dyne's stock.
• Despite reporting a loss per share (EPS) of ($0.97), Dyne Therapeutics exceeded analysts' expectations and currently has an average rating of "Buy" with a consensus price target of $33.80.

Vanguard Group Inc. raised its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 10.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 7,406,344 shares of the company's stock after buying an additional 702,418 shares during the period. Vanguard Group Inc. owned 6.52% of Dyne Therapeutics worth $77,470,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in DYN. Wells Fargo & Company MN increased its stake in Dyne Therapeutics by 54.5% in the 4th quarter. Wells Fargo & Company MN now owns 38,754 shares of the company's stock valued at $913,000 after buying an additional 13,677 shares during the last quarter. Raymond James Financial Inc. acquired a new stake in Dyne Therapeutics in the 4th quarter valued at $2,340,000. Marshall Wace LLP acquired a new position in shares of Dyne Therapeutics during the 4th quarter worth about $577,000. MetLife Investment Management LLC increased its stake in shares of Dyne Therapeutics by 5.9% during the 4th quarter. MetLife Investment Management LLC now owns 49,467 shares of the company's stock worth $1,165,000 after purchasing an additional 2,748 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in shares of Dyne Therapeutics by 887.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 16,018 shares of the company's stock worth $377,000 after purchasing an additional 14,396 shares during the last quarter. 96.68% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Dyne Therapeutics

In other news, CEO John Cox purchased 100,000 shares of the business's stock in a transaction dated Monday, July 14th. The stock was bought at an average price of $9.11 per share, with a total value of $911,000.00. Following the acquisition, the chief executive officer owned 242,179 shares in the company, valued at approximately $2,206,250.69. The trade was a 70.33% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 14.14% of the company's stock.

Dyne Therapeutics Stock Performance

NASDAQ DYN traded up $0.32 during trading on Thursday, reaching $13.96. The company's stock had a trading volume of 2,199,459 shares, compared to its average volume of 2,626,994. The company has a current ratio of 16.83, a quick ratio of 16.83 and a debt-to-equity ratio of 0.17. The firm has a market capitalization of $1.99 billion, a price-to-earnings ratio of -3.61 and a beta of 1.08. Dyne Therapeutics, Inc. has a 12 month low of $6.36 and a 12 month high of $46.26. The firm has a 50 day moving average price of $10.33 and a 200 day moving average price of $11.18.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last posted its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. As a group, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Analysts Set New Price Targets

DYN has been the topic of several recent analyst reports. Guggenheim restated a "buy" rating and set a $50.00 price objective on shares of Dyne Therapeutics in a research note on Wednesday, June 18th. Stifel Nicolaus lowered their price objective on shares of Dyne Therapeutics from $66.00 to $36.00 and set a "buy" rating on the stock in a research note on Thursday, July 31st. Robert W. Baird lowered their price objective on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating on the stock in a research note on Wednesday, June 18th. Raymond James Financial upgraded shares of Dyne Therapeutics from an "outperform" rating to a "strong-buy" rating and boosted their price objective for the stock from $31.00 to $35.00 in a research note on Monday. Finally, Royal Bank Of Canada decreased their price target on shares of Dyne Therapeutics from $25.00 to $23.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 29th. Three equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $34.07.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.